New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:03 EDTOXFDOxford Immunotec growth looks robust, says RW Baird
Baird believes the growth outlook for Oxford Immunotec remains robust and they believe the company is in the early stages of penetrating the large global market for latent TB testing. Shares are Outperform rated and price target raised to $27 from $21.
News For OXFD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 11, 2014
08:56 EDTOXFDOxford Immunotec shares remain materially undervalued, says Cowen
Cowen said Oxford Immunotec shares remain materially undervalued following the company's technology day yesterday. The firm cited the company's pipeline and market opportunity along with solid management execution. Cowen reiterated its Outperform rating and $20 price target on Oxford Immunotec shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use